MARKET

CELC

CELC

Celcuity Inc
NASDAQ
90.79
-1.99
-2.14%
After Hours: 90.79 0 0.00% 19:34 08/10 EDT
OPEN
92.35
PREV CLOSE
92.78
HIGH
93.67
LOW
90.14
VOLUME
787.05K
TURNOVER
--
52 WEEK HIGH
151.02
52 WEEK LOW
44.42
MARKET CAP
4.43B
P/E (TTM)
-23.3082
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELC last week (0803-0807)?
Weekly Report · 22h ago
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Barchart · 08/03 19:19
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
Seeking Alpha · 08/03 13:35
Weekly Report: what happened at CELC last week (0727-0731)?
Weekly Report · 08/03 09:05
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
PR Newswire · 08/03 05:08
Celcuity announces NCCN recommendation for Revtorpyk combination
TipRanks · 07/30 13:40
Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy
Benzinga · 07/30 12:34
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Barchart · 07/28 18:50
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.